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Depolymerized holothurian glycosaminoglycan (DHG), a novel Anticoagulation is required during hemodialysis in or-
alternative anticoagulant for hemodialysis, is safe and effective der to prevent clot formation in the dialyzer and hemodi-
in a dog renal failure model. alysis catheters. The large surface of the artificial mem-Background. Depolymerized holothurian glycosaminogly-
branes of the dialyzer and modified hemodynamics incan (DHG) is a new agent with anticoagulant properties quite
the extracorporeal system contribute to activation of thedifferent from those of unfractionated heparin (UFH) and low-
molecular-weight heparin (LMWH) in terms of antithrombin clotting system during dialysis. Clinically, unfractionated
III–dependency, and exerts an antithrombotic effect with less heparin (UFH) is commonly used as an anticoagulant for
bleeding than UFH and LMWH in vivo. In this study, the anti- hemodialysis. There are, however, certain situations incoagulant and hemorrhagic effects of DHG were investigated
which it is associated with adverse effects, such as increasedon hemodialysis in a dog model of renal failure and compared
bleeding tendency [1, 2] and disturbance of lipid metabo-with those of UFH, LMWH, and nafamostat mesilate (FUT).
Methods. The dog renal failure model was prepared by 7/8 lism [3]. Hemodialysis using UFH has a significant risk
renal artery ligation. Effectiveness was based on completion of clinically important hemorrhage, with a reported inci-
of 3-hour hemodialysis, no marked clot deposition in the extra-
dence of 10% to 26% [1]. To diminish these complications,corporeal circuit, and permeability of blood urea nitrogen (BUN)
various alternative methods have been developed. Re-and creatinine. Template bleeding was measured by determining
the hemoglobin content of the blood from the wound. cently, nafamostat mesilate (FUT), a serine protease in-
Results. DHG induced no major bleeding or clot formation hibitor [4–6], and low-molecular-weight heparin (LMWH)
during 3-hour hemodialysis, in contrast to UFH and LMWH, [7, 8] have been used as alternatives to heparin for hemo-
each of which induced marked bleeding. These glycosaminogly-
dialysis in patients with high risk of hemorrhage to re-cans (GAGs) were equally effective in decreasing plasma levels
duce bleeding risk [6, 7, 9]. However, they have severalof BUN and creatinine. On the other hand, dogs treated with
FUT failed to complete 3-hour hemodialysis. These anticoagu- problems, such as induction of hyperkalaemia [10] and
lants prolonged activated partial thromboplastin time (APTT) anaphylactoid reaction [11, 12], in addition to increased
to different extents and GAGs prolonged thrombin clotting bleeding complications in clinical use [13].time markedly but FUT did not.
Depolymerized holothurian glycosaminoglycan (DHG)Conclusion. Our findings suggest that thrombin clotting time
is a fragment of glycosaminoglycan (GAG) extractedprolongation can contribute to prevention of clot formation in
extracorporeal circuits, and the non-antithrombin III–dependent from sea cucumber with a molecular weight of approxi-
activities of DHG may be related to its low risk of hemorrhage mately 15,000. It has been produced on an industrial scale,
for hemodialysis. DHG appears to be promising as an alterna-
and its unique fucose-containing structure has been clari-tive anticoagulant with low risk of hemorrhage for hemodialysis.
fied [14]. It was demonstrated that the anticoagulant
mechanism of action of DHG is quite different from those
of UFH and LMWH, i.e., it has two different antithrom-
bin III–independent activities: one is heparin cofactor II–
dependent thrombin inhibition, and the other is antithrom-Key words: anticoagulant, glycosaminoglycan, DHG, dog with renal
failure, hemodialysis. bin III– and heparin cofactor II–independent inhibition of
the coagulation cascade. This heparin cofactor–indepen-Received for publication February 22, 2002
dent activity of DHG inhibits the function and formationand in revised form September 6, 2002
Accepted for publication November 21, 2002 of the factor IXa-factor VIIIa complex [15, 16]. These
mechanisms of anticoagulation in vitro were confirmed 2003 by the International Society of Nephrology
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to act efficiently in vivo using antithrombin III–depleted III activity, 0.0 heparin units/mg; antithrombin activity
(heparin cofactor II), 101.9 heparin units/mg; antifactormice [17]. In addition, DHG acts as an antithrombotic,
with less bleeding risk than UFH and LMWH in rats Xa activity antithrombin III), 0.0 heparin units/mg; APTT
prolongation activity, 1013 DHG units/mg; average molec-and dogs [18, 19], and it has been speculated that its anti-
thrombin III–independent properties may be related to ular weight of 12,500] [17, 18].
GAGs were administered on a gravimetric basis, ex-its lower risk of inducing bleeding in vivo [18, 20]. In
addition, we provided evidence that DHG was efficient cept for DHG, which was given on a unit basis with 1
mg/kg DHG equivalent to 1000 DHG units/kg based onand had less risk of inducing hemorrhage as an anticoag-
ulant for a hemodialysis model in normal dogs. APTT prolongation activity determined using a DHG
standard.In the present study, we prepared a male renal failure
beagle model by 7/8 renal artery ligation to mimic actual
Hemodialysis designclinical conditions. Using this model, the anticoagulation
and bleeding risk of DHG for hemodialysis were investi- Anesthesia was induced with sodium pentobarbital
(30 mg/kg, intravenously; Abbott Laboratories, Northgated and compared to those for UFH, LMWH, FUT,
and a control, and we evaluated whether DHG is promis- Chicago, IL, USA) and maintained (5 mg/kg/hour) dur-
ing the experiment. Animals were placed on an operatinging for clinical use.
table with a weighing facility, intubated, and their body
temperature kept at 38C with an electric blanket. Cathe-
METHODS
ters inserted into the right femoral artery and left femoral
Animal model vein were connected to an extracorporeal hemodialysis
circuit system (DBB-22B; Nikkiso Co., Ltd., Tokyo, Japan),Male beagle dogs with a body weight between 9 and
12 kg were obtained from Yakken Farm Co., Ltd. These with its hollow-fiber dialyzer [A-04H of 0.4 m2 (cupro-
phan); Kawasumi Lab., Tokyo, Japan] perfused with bio-experiments were reviewed and approved by the Animal
Ethics Committee of Taiho Pharmaceutical Co., Ltd. carbonate dialysate (Kindaly Solution AF-2; Fuso, Osaka,
Japan). The extracorporeal circuit was primed prior to(Tokyo, Japan). In total, 7/8 renal mass reduction was
performed in two surgeries performed 3 days apart; the dialysis with UFH (2000 IU/L) containing saline. The
blood flow rate was kept at 50 mL/minute, and the dialy-first involved mass reduction by ligation (3/4) of the right
arterial branch (stage 1), and the second involved total sate flow rate at 330 mL/minute. During hemodialysis,
each arterial and venous chamber was connected to aleft-side nephrectomy (stage 2). Three days after the
second-stage surgery, the model animals were confirmed spectrumed DTX-PLUS transducer (Becton Drive, Frank-
lin Lakes, NJ, USA) to monitor pressure, which wasto have plasma levels of blood urea nitrogen (BUN)
elevated to approximately 50 to 100 mg/dL with develop- recorded using a RMP-6018M 8-channel dymograph (Ni-
hon Kohden, Tokyo, Japan). Another catheter was in-ment of moderate-to-marked azotemia, and were then
randomly allocated to groups before hemodialysis. serted into the left femoral artery and blood pressure
was monitored in identical fashion.
Materials Previously, we performed a preliminary study to estab-
lish the minimum effective doses of DHG and other drugsThe following materials were purchased as indicated:
UFH (porcine mucosa; Nacalai Tesque, Inc., Kyoto, Ja- on hemodialysis for 5 hours in normal dog. It was possible
to complete it with DHG at a dose of 5 mg/kg bolus pan), LMWH (porcine intestinal mucosa; Sigma Chemi-
cal Co., Ltd., St. Louis, MO, USA), and FUT (Torii Phar- 2.5 mg/kg/hour drip infusion but not at 3 mg/kg bolus 
1.5 mg/kg/hour drip infusion; it could be completed withmaceutical Co., Ltd., Tokyo, Japan). DHG was prepared
in-house from GAG extracted from sea cucumbers by UFH at a dose of 1 mg/kg bolus  0.5 mg/kg/hour drip
infusion but not at 0.5 mg/kg bolus  0.25 mg/kg/hourdepolymerization using hydrogen peroxide. The specific
activities and molecular weight of the GAGs used were drip infusion; it could be completed with LMWH at a
dose of 3 mg/kg bolus 1.5 mg/kg/hour drip infusion butas follows: UFH [antithrombin III activity, 205.7 heparin
units/mg; antithrombin activity (heparin cofactor II), 184.8 not at 1 mg/kg bolus  0.5 mg/kg/hour drip infusion; it
could be completed with FUT at a dose of 3 mg/kg/hourheparin units/mg; antifactor Xa activity (antithrombin III),
191.5 heparin units/mg; activated partial thromboplastin drip infusion but not at 1 mg/kg/hour drip infusion. To
confirm the reproducibility, these hemodialysis studiestime (APTT) prolongation activity, 3702 DHG units/mg;
average molecular weight of 15,000]; LMWH [antithrom- were performed twice at each dose. Based on these results,
we established the minimum effective doses for normalbin III activity, 58.7 heparin units/mg; antithrombin ac-
tivity (heparin cofactor II), 21.6 heparin units/mg; anti- dog [19]. In this study, hemodialysis was carried out at
the minimum effective dose of each anticoagulant asfactor Xa activity (antithrombin III), 74.4 heparin units/mg;
APTT prolongation activity, 1033 DHG units/mg; aver- follows: DHG, 5 mg/kg bolus 2.5 mg/kg/hour drip infu-
sion; UFH, 1 mg/kg bolus 0.5 mg/kg/hour drip infusion;age molecular weight of 8000]; and DHG [antithrombin
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LMWH, 3 mg/kg bolus  1.5 mg/kg/hour drip infusion; At the end of dialysis, template bleeding of the ear
surface was measured as follows. A template deviceand FUT, 3 mg/kg/hour drip infusion. DHG, UFH, and
LMWH were administered as a bolus injection into the (Simplate, Organon Teknika Co., Durham, MC, USA)
was applied to the surface of the ear, with care takenfemoral vein followed by continuous infusion into the
inlet of the circuit line. FUT was directly infused continu- to avoid large veins. Blood from the wound was then
carefully taken up with filter paper every 1 minute untilously into the extracorporeal circuit [5] to avoid degrada-
tion in the dog. In the control group, 10 mL saline was complete arrest of bleeding for 1 minute. If bleeding
from the incisions had not stopped after 120 minutes,intravenously injected as a bolus followed by continuous
saline infusion (10 mL/hour) instead of anticoagulants. measurement was stopped at that time. The paper was
placed in a defined volume of saline and hemoglobinThe possible hemodialysis period (until the difference
in pressure values between the inlet and outlet of the content was determined using a hemoglobin kit (Wako
Hemoglobin B Test; Wako Pure Chemical Co.) anddialyzer reached 200 mm Hg) was determined and lim-
ited the maximum duration to 3 hours. Following dial- bleeding expressed as blood loss.
ysis, the inlet of the line was clamped, removed from
GAG plasma concentrationsthe catheter, and attached to a saline bag in order to
push the blood in the lines back into the dog. The venous GAG plasma concentrations were determined using
a DS kit (Stago Diagnostica, Asnieres, France) by mea-line was then disconnected, both wounds were sutured,
and the dog was returned to its cage. suring antithrombin activity in the presence of bovine
heparin cofactor II. Each GAG was used as the cali-At the end of hemodialysis, residual blood clot in the
extracorporeal circuit was determined. Residual blood brator.
clot in the dialyzer was classified into four grades based
Statistical analysison visual assessment as follows: 0  no clot formation
observed; 1  clot formation observed in several fibers; All group data were expressed as mean values and
SD unless stated otherwise. Differences between groups2  clot deposits in hollow fibers in a fasciculus; 3 
clot formation in about half of the fibers; and 4 dialysis in residual blood clot in the dialyzer and clot deposition
in drip chambers were tested statistically by the Wilcoxonnot maintainable due to clot formation. Clot deposits
remaining in the drip chamber were expressed as the test. Student paired t test was used for analysis of blood
loss. All other statistical testing was performed by one-hemoglobin content if blood clot was present in it. The
blood clot was hemolyzed by sonication in a defined way analysis of variance (ANOVA) followed by Dun-
nett’s test. A P value of less than 0.05 was consideredvolume of saline, and its hemoglobin content measured
using a hemoglobin kit (Hemoglobin B Test Wako, Wako to be statistically significant.
Pure Chemical Co., Osaka, Japan).
RESULTSLaboratory tests
Efficacy and safety of anticoagulants in experimentalBefore, during, and after hemodialysis, blood was
hemodialysis in dogs with renal failuretaken from the femoral artery into 3.8% sodium citrate
(1 volume to 9 volumes of blood) or a sample bottle con- When hemodialysis in dogs with renal failure was con-
ducted without an anticoagulant (control), the differencetaining ethylenediaminediaminetetraacetic acid (EDTA)
(Sysmex; Toa Medical Electronics Company, Ltd., Kobe, in pressure between the inlet and outlet of the dialyzer
reached 200 mm Hg within approximately 60 minutes.Japan). Plasma was separated by centrifugation at 1500 g
for 10 minutes at 4C, and stored at 80C until assay. With DHG (5 mg/kg bolus  2.5 mg/kg/hour drip infu-
sion), with UFH (1 mg/kg bolus  0.5 mg/kg/hour dripAPTT and thrombin clotting time were determined
using a commercially available APTT reagent (Platelin infusion), and with LMWH (3 mg/kg bolus  1.5 mg/kg/
hour drip infusion), 3-hour hemodialysis was completedLS, Organon Teknika Co., Durham, NC, USA) and dog
thrombin (final 1 unit/mL) purified in our laboratory in all five dogs of each group (Table 1). With FUT (3 mg/
kg/hour drip infusion), the difference in pressure values[21, 22].
White blood cell count, hematocrit, and platelet count between the inlet and outlet of the dialyzer reached 200
mm Hg. Additionally, even when hemodialysis with FUTwere measured with an automatic analyzer (NE-6000,
Toa Medical Electronics Company, Ltd.). BUN was mea- (5 and 10 mg/kg/hour drip infusion) was performed twice
at each dose, no dogs could undergo an entire 3 hoursured using a Wako BUN Test and creatinine using a
Wako CRN Test (Wako Pure Chemical Co., Osaka, Ja- hemodialysis (data not shown).
With hemodialysis using DHG, UFH, and LMWH, thepan). Triglyceride was measured using a Wako Triglycer-
ide E-HA Test (Wako Pure Chemical Co.) and nonester- difference in pressure values between the inlet and outlet
of the dialyzer was stably maintained at about 150 mm Hgified fatty acid (NEFA) using a Wako NEFA-HA Test
(Wako Pure Chemical Co.). throughout the 3-hour dialysis period (data not shown).
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Table 2. Anticoagulant effects of DHG, UFH, LMWH, and FUTTable 1. The mean period of hemodialysis and the percent efficacy




Efficacy of dialysis %Period of
each of five dogsBolus Drip infusion hemodialysis Dose
(0 to 4)Drug mg/kg mg/kg/hour hour BUN Creatinine
Bolus Drip-infusion
Control 1.010.55 40.56.9 41.66.3 Drug mg/kg mg/kg/hour 0 1 2 3 4 Significance
DHG 5 2.5 3.000.00b 66.02.0b 55.13.8a
UFH 1 0.5 3.000.00b 66.12.9b 55.95.9a Control 0 0 0 3 2
DHG 5 2.5 1 4 0 0 0 bLMWH 3 1.5 3.000.00b 64.82.7a 54.26.6a
FUT 0 3 1.220.14 43.95.5 43.96.0 UFH 1 0.5 1 0 3 1 0 a
LMWH 3 1.5 0 4 1 0 0 bAbbreviations are: BUN, blood urea nitrogen; DHG, depolarized holothurian
FUT 0 3 0 0 0 0 5 NSglycosaminoglycans; FUT, nafamostat mesilate; LMWH, low-molecular-weight
heparin; UFH, unfractionated heparin. All data are shown as mean  SD (N  Abbreviations are: DHG, depolarized holothurian glycosaminoglycans; FUT,
5). a P  0.05; b P  0.01 vs. control by Dunnett’s test. There is no difference nafamostat mesilate; LMWH, low-molecular-weight heparin; UFH, unfraction-
among the glycosaminoglycans (GAGs). ated heparin. Clot formation in the dialyzer classified by visual inspection after
hemodialysis (see Methods section). Numbers indicate the number among five
dogs classified for each score. Differences between groups in residual blood clot
in the dialyzer were analyzed by Wilcoxon’s test.
a P  0.05; b P  0.01 vs. control
The average duration of stable hemodialysis and effects
as an anticoagulant on hemodialysis to reduce creatinine
and BUN are shown in Table 1. Dialysis with DHG was
seconds, and FUT to 56.5 seconds. FUT resulted in ancompleted effectively, as well as those with UFH or
APTT of more than 200 seconds in the dialysis circuitLMWH, since the percent decreases in plasma creatinine
(sampling at the inlet of the dialyzer). DHG, UFH, andand BUN were equivalent with these GAGs. With FUT
LMWH prolonged thrombin clotting time more thanand saline control, 3-hour hemodialysis could not be
200 seconds during hemodialysis. FUT only minimallycompleted, resulting in failure to reduce creatinine and
prolonged thrombin clotting time in the inlet and outletBUN. There was no difference between FUT and the
of the circuit. Even with high doses (5 and 10 mg/kg/hourcontrol in either possible period of hemodialysis or per-
drip infusion), FUT only slightly prolonged thrombin
centage decreases of creatinine and BUN. Table 2 shows
clotting time (data not shown).
values for residual blood clots in the dialyzer. Large Effects on changes in white blood cell count, hemato-
thrombotic patches in the dialyzer plate were observed crit, and platelet count during hemodialysis are shown
in the control and FUT groups. DHG, UFH, and LMWH in Figure 3. Although a transient decrease in platelet
decreased blood clots in the dialyzer, and the scores for count was observed in surgical stage 2, platelet count
them were below the control value. Figure 1 shows the recovered on the day of hemodialysis. During hemodial-
amounts of blood clot remaining in the inlet and outlet ysis, platelet count exhibited no significant differences
of drip chambers. Significant clots were formed within the among GAGs, but constantly decreased during hemodi-
bubble trap in the control group. DHG, similar to UFH alysis using FUT until 1 hour after injection. No signifi-
and LMWH, inhibited the clot formation in the chamber cant differences among anticoagulants were observed in
of the extracorporeal circuit. In contrast to the degree changes in white blood cell count. Compared with that
of residual clot in the dialyzer, blood clot in the chamber in normal dogs, white blood cell count in dogs with renal
on both sides was less in the FUT group than in the failure tended to increase. In our hemodialysis model,
control. These results indicate that FUT was unable to leukopenia in the early phase of the hemodialysis session
maintain extracorporeal circulation because of the com- and rebound was observed, as in clinical hemodialysis
plete occlusion of the dialyzer. [23]. Although hematocrit did not differ greatly among
GAGs during hemodialysis, it tended to decrease in the
Laboratory tests UFH and LMWH groups at 24 hours after hemodialysis.
The effects of anticoagulants on APTT and thrombin However, there was no difference among the GAGs in
clotting time in blood obtained from the inlet of a dialysis changes in hematocrit.
circuit during hemodialysis are shown in Figure 2. The Regarding lipid levels, nonesterified fatty acids tran-
baseline values of APTT and thrombin clotting time in siently increased during hemodialysis using GAGs and
dogs with renal failure (APTT, 13.1 seconds; thrombin FUT but remained nearly within the normal range (0.3
clotting time, 15.6 seconds on average) tended to be to 0.7 meq/L) (data not shown). No significant change
slightly shortened than in normal dogs (APTT, 14.0 sec- in triglyceride was observed during hemodialysis with
onds; thrombin clotting time, 16.9 seconds on average). any anticoagulant (data not shown). There was no differ-
At 1 hour after injection, APTT was prolonged by DHG ence among the four anticoagulants in either nonesteri-
to about 5.4 times (70.9 seconds) the baseline value. fied fatty acids or triglyceride levels.
The effects of anticoagulants on bleeding during he-UFH prolonged APTT to 33.6 seconds, LMWH to 41.4
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Fig. 1. Anticoagulant effects of depolymer-
ized holothurian glycosaminoglycan (DHG),
unfractionated heparin (UFH), low-molecu-
lar-weight heparin (LMWH), and nafamostat
mesilate (FUT) on clot deposition in drip
chambers of the extracorporeal circuit. The
amount of residual blood clot in each chamber
is presented as hemoglobin content (see Meth-
ods section). Results indicate the mean  SD
(N  5). *P  0.05, **P  0.01 vs. control by
Wilcoxon’s test. There is no difference among
the glycosaminoglycans (GAGs).
Fig. 2. Effects on activated partial thrombo-
plastin time (APTT) (A) and thrombin clot-
ting time (B) of depolymerized holothurian
glycosaminoglycan (DHG), unfractionated hep-
arin (UFH), low-molecular-weight heparin
(LMWH), and nafamostat mesilate (FUT). All
samples were taken directly from the femoral
artery except as indicated. Each point indi-
cates the mean  SD of five dogs. Normal
APTT, 13.1 seconds; normal thrombin clotting
time, 14.9 seconds. Symbols are: () saline
control; () DHG, 5 mg/kg bolus 2.5 mg/kg/
hour drip infusion; () UFH, 1 mg/kg bolus
0.5 mg/kg/hour drip infusion; () LMWH, 3
mg/kg bolus  1.5 mg/kg/hour drip infusion;
() FUT, 3 mg/kg/hour drip infusion; () FUT,
3 mg/kg/hour drip infusion (sampled from ex-
tracorporeal circuit, inlet).
Fig. 3. Effects on platelet count (A), white blood cell count (B), and hematocrit (C ) of depolymerized holothurian glycosaminoglycan (DHG),
unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and nafamostat mesilate (FUT). Each point indicates the mean  SD of
five dogs. Symbols are: () saline control; () DHG, 5 mg/kg bolus  2.5 mg/kg/hour drip infusion; () UFH, 1 mg/kg bolus  0.5 mg/kg/hour
drip infusion; () LMWH, 3 mg/kg bolus  1.5 mg/kg/hour drip infusion; () FUT, 3 mg/kg/hour drip infusion. *P  0.05, **P  0.01 vs. control
by Dunnet’s test, and there is no difference among the glycosaminoglycans (GAGs).
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an animal model of renal failure in order to mimic clinical
conditions, and compared it to UFH, LMWH, FUT, and
the control. At the minimum effective dose of each anti-
coagulant determined previously in normal dogs [19],
3-hour hemodialysis was completed with DHG, UFH,
and LMWH. The percent decreases in plasma creatinine
and BUN during hemodialysis were equivalent for these
GAGs, indicating that dialysis with DHG was completed
effectively as well as those with UFH or LMWH. More-
over, effective dialysis with DHG was achieved with a
low risk of bleeding, in contrast to UFH and LMWH,
which featured large amounts of bleeding (Fig. 4), consis-
tent with the findings of our previous studies in rats [18]
and dogs [19]. As mentioned above, the antithrombin
III–independent inhibitory effects of DHG on the blood
coagulation system differ markedly from those of both
Fig. 4. Hemorrhagic effects of depolymerized holothurian glycosami-
heparins. Although it has been speculated that prolongednoglycan (DHG), unfractionated heparin (UFH), and low-molecular-
weight heparin (LMWH). The template device was applied to the ear bleeding caused by GAGs in animals correlates with
surface with care taken to avoid large veins, and blood from the wound antithrombin activity [18], the difference in risk of hem-
was collected. Blood loss is expressed as hemoglobin content (see Meth-
orrhage may depend on thrombin inhibition via anti-ods section). Template bleeding was measured before surgery per-
formed to induce renal failure (stage 1), prehemodialysis (HD-pre), thrombin III. Dermatan sulfate is known to accelerate
and at 3 hours after the start of hemodialysis (HD-3 hr). Abbreviations thrombin inhibition by heparin cofactor II [24], and this
are: D, DHG, 5 mg/kg bolus  2.5 mg/kg/hour drip infusion; U, UFH,
is probably the main anticoagulant effect of this GAG.1 mg/kg bolus  0.5 mg/kg/hour drip infusion; L, LMWH, 3 mg/kg
bolus  1.5 mg/kg/hour drip infusion. Results indicate the mean  SD In one study, dermatan sulfate functioned as an effective
(N  5). *P  0.05 vs. prehemodialysis values by paired t test. anticoagulant agent for hemodialysis in patients with
chronic renal failure [25]. In that study, dermatan sulfate
prolonged thrombin clotting time, but did not increase
bleeding, supporting our hypothesis. Although in themodialysis are shown in Figure 4. In our study, blood
present study, both heparins induced severe bleeding,loss was almost the same in normal dogs as in those with
this is rarely seen clinically. This may be because dosesrenal failure. Although DHG had no marked effect on
of both of the heparins used in dogs were much higherbleeding during hemodialysis, UFH and LMWH each
than those used in humans. Moreover, the enhancementsignificantly enhanced bleeding during hemodialysis. The
of fibrinolysis by heparins [26, 27] may also be relatedbleeding time with DHG was 6.9 1.0 minutes; that with
to the long bleeding time observed in this study.UFH was 60.0  39.4 minutes, and with LMWH it was
In contrast to GAGs, no dogs in which FUT was used94.0 26.1 minutes, with prehemodialysis values of 5.7
could undergo 3 hours of hemodialysis. Patients with0.9 minutes (mean  SD).
renal failure are in a hypercoagulable state and hemodi-
alysis promotes this state [28, 29]. Therefore, hemodialy-GAG plasma concentrations
sis in dogs with renal failure may require more powerfulFigure 5 shows GAG plasma concentrations during
anticoagulation treatment than in normal dogs. Basedand 24 hours after hemodialysis. Plasma concentrations
on a previous study [19] and the present study, we specu-of DHG, UFH, and LMWH during hemodialysis when
late that prolongation of thrombin clotting time is a keythese agents were administered as a bolus injection into
factor in achievement of hemodialysis in our beagle model.the femoral vein followed by continuous infusion directly
Although sufficient prolongation of APTT by FUT wasinto the extracorporeal circuit were 73.4 g equivalent/
observed, FUT only minimally prolonged thrombin clot-mL, 13.9 g equivalent/mL, and 48.3 g equivalent/mL,
ting time in the extracorporeal circuit in our hemodialysisrespectively, at 3 hours after the start of hemodialysis.
model. Therefore, it was assumed that FUT was unableGAGs did not pass through the membrane of the dia-
to inhibit blood clot formation in the dialyzer becauselyzer nor did they interact with it, since there were no
of incomplete inhibition of thrombin. In agreement withdifferences in GAG plasma levels between the inlet and
our results, Matsuo et al [30] have reported that despiteoutlet of the dialyzer (Fig. 5).
sufficient prolongation of APTT in the circuit, FUT was
less effective in suppressing thrombin generation than
DISCUSSION UFH. From these findings, FUT might fail to allow com-
pletion of hemodialysis. On the other hand, this issueIn the present study, we investigated the efficacy and
safety of DHG as an anticoagulant for hemodialysis in does not occur in humans. There are three possible rea-
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Fig. 5. Plasma concentrations of depolymer-
ized holothurian glycosaminoglycan (DHG)
(A), unfractionated heparin (UFH) (B), and
low-molecular-weight heparin (LMWH) (C )
during hemodialysis in dogs with renal failure.
Each point indicates the mean SD (N  5).
Plasma concentrations of DHG, UFH, and
LMWH were assayed by measuring anti-
thrombin activity in the presence of bovine
heparin cofactor II (see Methods section).
Symbols are: () sampled directly from the
femoral artery; () sampled from the extra-
corporeal circuit (ahead of the dialyzer); ()
sampled from the extracorporeal circuit (be-
yond the dialyzer).
sons. First, the comparative activity of thrombin of dogs in whole blood can be used to monitor the effect of
DHG (data not shown). In addition, immunogenicity andis higher than that of humans. Furthermore, it is sup-
posed that renal failure status works more hypercoagula- antigenicity of DHG were evaluated by the active sys-
temic anaphylaxis (ASA) test and passive cutaneous ana-bility than normal status, especially in hemodialysis in
dogs with renal failure. Therefore, strong antithrombin phylaxis (PCA) test using guinea pigs and mice/rats. Nei-
ther immunogenicity nor antigenicity was observed inactivity may be needed to prevent thrombosis in the dial-
ysis circuit in renal failure dogs. Second, dialyzer blood these animals after repeated immunization with DHG
(data not shown). However, since some cases of hyper-flow in dogs is much lower than in humans, which might
increase clotting tendency. Finally, this study was per- sensitivity to heparinoid have been reported [34], subcu-
taneous testing of DHG may be necessary to determineformed with a cuprophan membrane, which might on its
own induce coagulation, and the results might have been whether this agent is acceptable for patients.
In the present study, it was demonstrated that DHGdifferent with the use of more biocompatible membranes.
In the clinical use of anticoagulants, some problems functioned as effectively as UFH and LMWH as an anti-
coagulant for experimental hemodialysis in dogs withinclude clearance of anticoagulant in renal failure, avail-
ability of antidotes, and monitoring tests. In this study, renal failure, and that it had no major risk of inducing
bleeding, unlike UFH and LMWH. These anticoagulantswe measured GAG plasma concentrations during and
at 24 hours after hemodialysis. Despite use of the same markedly extended thrombin clotting time, but FUT,
which yielded insufficient thrombin clotting time prolon-doses as in normal dogs, plasma concentrations of DHG
and LMWH at 3 hours after the start of hemodialysis gation, failed to enable completion of 3-hour hemodialy-
sis. These findings suggest that efficacy of DHG is associ-were higher than those in normal dogs (DHG, 38.2 versus
73.4 g equivalent/mL; LMWH, 32.9 versus 48.3 g ated with thrombin clotting time prolongation and that
its non-antithrombin III–dependent effects are relatedequivalent/mL) [19]. These findings suggest that DHG
and LMWH were retained in the blood of dogs with renal to its low risk of inducing bleeding. DHG should thus
be useful as an anticoagulant for hemodialysis.failure. However, they had been completely cleared by
24 hours after the hemodialysis session. DHG is partially
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